SyntekabioMake Bio Seen
Accelerating
Bio Innovation
Our AI-powered platforms accelerate the entire drug discovery process — enabling faster more precise innovation across small molecules, antibodies, and cancer vaccines.
At a glance
Syntekabio in brief
- Syntekabio combines AI, data, and supercomputing infrastructure to accelerate drug discovery decisions.
- The company operates AI-powered platforms including SM-ARS, AB-ARS, NEO-ARS, DeepMatcher, and LM-VS.
- Its ecosystem connects research, asset discovery, pipelines, collaboration, and infrastructure services.
SM-ARS®
Al-based small-molecule drug discovery
Synthetic Drugs
AB-ARS®
Al-based antibody candidate discovery
Antibody
NEO-ARS®
Al-based neoantigen discovery & vaccine design
Cancer Vaccine
DEEPMATCHER®
Language model for protein–compound interaction prediction
Synthetic DrugsCancer VaccineAntibody
LM-VS™
Language Model-based Virtual Screening
Syntekabio
AI SoftwareAl-Driven Drug Discovery Platform
Big DataLanguage Model and STB Cloud
Supercomputing PowerAl Bio Supercom Center
Syntekabio in Numbers
Drug Discovery Acceleration3x ↑
Patent Portfolio30 ⁺
Global Partnerships30 ⁺
Korea's AI Bio Supercom Center1 & Only
Latest News
SyntekaBio Enters ‘Assetization Phase’ for AI Asset Program
SyntekaBio Enters ‘Assetization Phase’ for AI Asset Program
2026.01.22
Syntekabio wins SI deal from HYBE’s Weverse unit
Syntekabio wins SI deal from HYBE’s Weverse unit
2025.12.18
SyntekaBio Licenses Out Five AI-Designed Multispecific Antibodies to Panolos
First Antibody License-Out Under AI-Driven Asset Program Commercialization of AI-Based Antibody Development Accelerates
2025.12.17